Literature DB >> 7927217

Serum type III procollagen peptide, type IV collagen 7S domain, central triple-helix of type IV collagen and tissue inhibitor of metalloproteinases in patients with chronic viral liver disease: relationship to liver histology.

Y Murawaki1, Y Ikuta, M Koda, H Kawasaki.   

Abstract

To assess the clinical value of serum biochemical markers, the aminoterminal peptide of type III procollagen, type IV collagen 7S domain, the central triple-helix of type IV collagen and tissue inhibitor of metalloproteinases, as a marker of hepatic fibrosis, we measured these four serum markers in 132 patients with chronic viral liver disease and compared these serum markers with liver histological findings. Serum levels of these markers increased closely with the progress of liver disease, and the abnormal percentages of type III procollagen peptide, type IV collagen 7S domain, central triple-helix of type IV collagen and tissue inhibitor of metalloproteinases in patients with cirrhosis were 97%, 95%, 83% and 48%, respectively. These four serum markers strongly correlated with the histological degree of periportal with or without bridging hepatocellular necrosis and of liver fibrosis and correlated weakly with the degree of intralobular degeneration and focal necrosis and the degree of portal inflammation. The correlation coefficients of serum type IV collagen 7S domain with periportal with or without bridging hepatocellular necrosis and with liver fibrosis were the highest among these four serum markers, suggesting that serum type IV collagen 7S domain is the most valuable diagnostic marker to assess the degree of liver fibrosis in chronic viral liver disease. When we assessed the ability of each serum marker to detect cirrhosis with a receiver operating curve, the best test was type IV collagen 7S domain, and the second best was type III procollagen peptide.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7927217     DOI: 10.1002/hep.1840200403

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  26 in total

1.  Usefulness of noninvasive transient elastography for assessment of liver fibrosis stage in chronic hepatitis C.

Authors:  Tadashi Takeda; Takahiro Yasuda; Yuji Nakayama; Mika Nakaya; Megumi Kimura; Mariko Yamashita; Ayumi Sawada; Koji Abo; Setsuko Takeda; Hiroki Sakaguchi; Susumu Shiomi; Hitoshi Asai; Shuichi Seki
Journal:  World J Gastroenterol       Date:  2006-12-28       Impact factor: 5.742

2.  Progress in non-invasive detection of liver fibrosis.

Authors:  Chengxi Li; Rentao Li; Wei Zhang
Journal:  Cancer Biol Med       Date:  2018-05       Impact factor: 4.248

3.  Role of α1 and α2 chains of type IV collagen in early fibrotic lesions of idiopathic interstitial pneumonias and migration of lung fibroblasts.

Authors:  Hirokazu Urushiyama; Yasuhiro Terasaki; Shinya Nagasaka; Mika Terasaki; Shinobu Kunugi; Takahide Nagase; Yuh Fukuda; Akira Shimizu
Journal:  Lab Invest       Date:  2015-05-25       Impact factor: 5.662

4.  Non-invasive diagnosis of liver fibrosis.

Authors:  Hiroyasu Morikawa; Norifumi Kawada
Journal:  Clin J Gastroenterol       Date:  2011-07-31

5.  Alpha-interferon improves liver fibrosis in chronic hepatitis C: clinical significance of the serum N-terminal propeptide of procollagen type III.

Authors:  F Serejo; A Costa; A G Oliveira; F Ramalho; A Batista; M C De Moura
Journal:  Dig Dis Sci       Date:  2001-08       Impact factor: 3.199

6.  Significant changes in the serum levels of IL-6, h-HGF, and type IV collagen 7S during the perioperative period of a hepatectomy: relevance to SIRS.

Authors:  K Namekata; S Takamori; K Kojima; T Beppu; S Futagawa
Journal:  Surg Today       Date:  2000       Impact factor: 2.549

7.  A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease.

Authors:  Yoshio Sumida; Masato Yoneda; Hideyuki Hyogo; Kanji Yamaguchi; Masafumi Ono; Hideki Fujii; Yuichiro Eguchi; Yasuaki Suzuki; Shunsuke Imai; Kazuyuki Kanemasa; Koji Fujita; Kazuaki Chayama; Kohichiroh Yasui; Toshiji Saibara; Norifumi Kawada; Kazuma Fujimoto; Yutaka Kohgo; Takeshi Okanoue
Journal:  J Gastroenterol       Date:  2010-09-15       Impact factor: 7.527

8.  Natural history of chronic hepatitis C in patients on hemodialysis: case control study with 4-23 years of follow-up.

Authors:  Kunio Okuda; Osamu Yokosuka
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

9.  Evidence for altered hepatic matrix degradation in genetic haemochromatosis.

Authors:  D K George; G A Ramm; L W Powell; L M Fletcher; N I Walker; L L Cowley; D H Crawford
Journal:  Gut       Date:  1998-05       Impact factor: 23.059

10.  Type IV collagen 7s domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stage.

Authors:  Masato Yoneda; Hironori Mawatari; Koji Fujita; Kyoko Yonemitsu; Shingo Kato; Hirokazu Takahashi; Hiroyuki Kirikoshi; Masahiko Inamori; Yuichi Nozaki; Yasunobu Abe; Kensuke Kubota; Satoru Saito; Tomoyuki Iwasaki; Yasuo Terauchi; Shinji Togo; Shiro Maeyama; Atsushi Nakajima
Journal:  J Gastroenterol       Date:  2007-05-25       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.